您好,欢迎您

【2023 ASCO】一文速览2023 ASCO年会妇科肿瘤领域重磅研究!

2023年05月11日
编译:肿瘤资讯
来源:肿瘤资讯

2023年第59届美国临床肿瘤学会(ASCO)年会将于美国芝加哥当地时间6月2日~6日盛大召开。近期,ASCO官网已公布会议日程和摘要题目。
 
【肿瘤资讯】整理了口头摘要专场(Oral Abstract Session)、LBA专场(Late-Breaking Abstract Session)、临床科学研讨会(Clinical Science Symposium)、壁报交流专场(Poster Discussion Session)的妇科肿瘤研究,与读者分享。

口头摘要专场- 妇科肿瘤

摘要号:5500

KEYNOTE-826: 帕博利珠单抗+化疗vs安慰剂+化疗一线治疗持续性、复发性或转移性宫颈癌的随机、双盲、3期研究的最终总生存期结果

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

讲者: Bradley J. Monk, MD | Division of Gynecological Oncology, HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix and Creighton University School of Medicine


摘要号:5501
标准放化疗( RTCT )前纳武利尤单抗+伊匹木单抗治疗方案对宫颈鳞状细胞癌FIGO IB3-IVA期患者的原位免疫影响:COLIBRI试验,一项GINECO研究

In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study

讲者:Isabelle Laure Ray-Coquard, MD, PhD | Centre Léon Bérard, University Claude Bernard Lyon 1


摘要号:5502
Triapine(T)联合顺铂放化疗(CRT)治疗局部晚期宫颈癌和阴道癌:结果来自NRG-GY 006,一项III期随机试验

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

讲者:Charles A. Leath, MD, MSPH | O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine


摘要号:5503
Dostarlimab治疗原发性晚期或复发性(A/R )子宫内膜癌( EC ):RUBY试验( ENGOT-EN6-NSGO/GOG-3031/RUBY)的盲法独立中心审查( BICR )结果

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

讲者:Matthew A. Powell, MD | National Cancer Institute sponsored NRG Oncology, Washington University School of Medicine


摘要号:5504
在ENGOT-EN6/GOG3031/RUBY试验中,与卡铂/紫杉醇相比,接受dostarlimab联合CP治疗的患者在原发性晚期或复发性子宫内膜癌(pA/rEC)中的患者报告结局(PRO)  

Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial

讲者:Mansoor Raza Mirza, MD | Rigshospitalet, Copenhagen University Hospital, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit


摘要号:5516
卡瑞利珠单抗联合阿帕替尼治疗至少1次系统治疗失败的晚期或复发性子宫内膜癌患者:一项单臂Ⅱ期试验

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial

讲者中国上海,复旦大学附属肿瘤医院 田文娟,MD, PhD


摘要号:5505
每周紫杉醇±ofranergene obadenovec (VB-111)治疗铂类耐药卵巢癌(OVAL Study / GOG 3018)的随机对照Ⅲ期试验

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018)

讲者:Rebecca Christian Arend, MD | University of Alabama at Birmingham


摘要号:LBA5506
度伐利尤单抗联合紫杉醇/卡铂 (PC)和贝伐珠单抗,随后对新诊断的肿瘤BRCA1/2未发生突变(non-tBRCAm)晚期卵巢癌(AOC)患者进行度伐利尤单抗,贝伐珠单抗和奥拉帕利维持治疗:来自随机、安慰剂( pbo )对照的Ⅲ期DUO - O试验的结果  

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial

讲者:Philipp Harter, MD, PhD | Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, and AGO


摘要号:5508
Luveltamab tazevibulin(STRO-002),一种抗叶酸受体α(FolRα)抗体药物偶联物(ADC),在FolRα表达广泛的复发性上皮性卵巢癌(OC)患者中的安全性和疗效: STRO-002-GM1 I期剂量扩展队列研究更新

Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort

讲者:Ana Oaknin, MD, PhD | Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital

LBA专场- LBA5507研究的介绍和讨论

摘要号:LBA5507
III期MIRASOL(GOG 3045/ENGOT-ov 55)研究:mirvetuximab soravtansine vs.铂类耐药、晚期高级别上皮性卵巢癌、原发性腹膜癌或输卵管癌中高叶酸受体α表达的研究者化疗选择的初始报告

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

讲者:Kathleen N. Moore, MD, MS | Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center

临床科学研讨会专场-利刃出鞘:妇科癌症的手术治疗

摘要号:5509
卵巢癌腹腔热灌注化疗Ⅲ期OVHIPEC-1试验随访10年的最终生存分析

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up

讲者:Lot Aronson, MD | The Netherlands Cancer Institute - Antoni van Leeuwenhoek


摘要号:5510
铂类敏感复发性上皮性卵巢癌的腹腔热灌注化疗:CHIPOR 随机 III 期试验

Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial

讲者:Jean-Marc Classe, MD, PhD | Institut de Cancérologie Ouest


摘要号:LBA5511
一项在低风险早期宫颈癌(LRESCC)患者中比较根治性子宫切除术和盆腔淋巴结清扫术(RH)与单纯子宫切除术和盆腔淋巴结清扫术(SH)的国际随机III期试验:由加拿大癌症试验组(CCTG CX.5-SHAPE)牵头的妇科癌症组间研究

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC):  A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE)

讲者:Marie Plante | Division of Gynecologic Oncology, Université Laval, CHU de Quebec

壁报交流专场-妇科肿瘤

摘要号:5512   | Poster Bd #: 207
吉西他滨联合或不联合ATR抑制剂berzosertib治疗铂类耐药卵巢癌的随机II期研究:最终总生存期(OS)和生物标志物分析

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses

讲者:Panagiotis A. Konstantinopoulos, MD | Dana-Farber Cancer Institute


摘要号:5513   | Poster Bd #: 208
在一项WEE1抑制剂azenosertib (ZN-c3)联合化疗(CT)治疗铂类耐药或难治性(R/R )上皮性卵巢癌、腹膜癌或输卵管癌( EOC )的1b期剂量递增研究中,cyclin E1表达与临床结局的相关性

Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC)

讲者:Joyce F. Liu, MD | Department of Medical Oncology, Dana-Farber Cancer Institute


摘要号:5514   | Poster Bd #: 209
LACOG 1018:一项针对ER/PR阳性的高级别浆液性或子宫内膜样卵巢癌、输卵管癌或腹膜癌患者二线化疗后哌柏西利联合来曲唑的Ⅱ期试验

A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018

讲者:Andreia Cristina De Melo, MD | Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Brazilian Gynecologic Oncology Group (EVA), Brazil; Division of Clinical Research and Technological Development- Brazilian National Cancer Institute (INCA)


摘要号:5515    | Poster Bd #: 210
ENGOT-ov60/GOG-3052/RAMP 201的初始疗效和安全性结果:一项avutometinib(VS-6766)± defactinib治疗复发性低级别浆液性卵巢癌(LGSOC)的II期研究

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

讲者:Susana N. Banerjee, PhD, FRCP, MA, MBBS | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI)


摘要号:5517  | Poster Bd #: 211
在罕见肿瘤中双重抗CTLA-4和抗PD-1阻断(DART)的II期篮子试验SWOG S1609:外阴癌  

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers

讲者:Young Kwang Chae, MD, MBA | Northwestern University


摘要号:5519   | Poster Bd #: 213
在局部晚期宫颈癌(LACVCa)患者中预先施用和共同施用纳武利尤单抗(Nivo),并同步放化疗(CCRT)随后Nivo维持治疗的疗效和最终安全分析:GOTIC-018I期试验的结果  

Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018

讲者:Kazuto Nakamura, MD, PhD | Department of Gynecology, Gunma Prefectural Cancer Center


摘要号:5520   | Poster Bd #: 214
新辅助卡瑞利珠单抗联合化疗治疗局部晚期宫颈癌(NACI研究):一项前瞻性、单臂、II期试验

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial

讲者中国湖北省武汉市,华中科技大学同济医学院附属同济医院 孙朝阳


摘要号:5528   | Poster Bd #: 215
晚期宫颈癌治疗:来自在线治疗决策工具的当代专家和医疗保健专业推荐的比较

Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool

讲者:Jerfiz Constanzo, PhD, MBA | Clinical Care Options


摘要号:5521   | Poster Bd #: 216
复发性卵巢癌(ROC)患者中尼拉帕利维持治疗的毒性特征和患者/医生之间的意见分歧:来自NIQOLE真实生活研究-GINECO研究的经验教训

Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study

讲者:Florence Joly, MD, PhD | Department of Medical Oncology, Centre François Baclesse


摘要号:5522   | Poster Bd #: 217
正常风险卵巢筛查研究(NROSS):该研究21年来的结果更新

The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update

讲者:Chae Young Han, Ph.D | The UT MD Anderson Cancer Center


摘要号:5523  | Poster Bd #: 218
Covid-19大流行对美国妇科恶性肿瘤患者就诊模式和临床结局的影响

The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States

讲者:Adrian Kohut, MD | City of Hope National Comprehensive Cancer Center


(本文依照报告日期和出场排序整理,如有错误或遗漏,敬请留言指正。)


资料来源

https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/search?q=&filters=%7B%22track%22:%5B%7B%22key%22:%22Gynecologic%20Cancer%22%7D%5D,%22sessionType%22:%5B%7B%22key%22:%22Education%20Session%22%7D,%7B%22key%22:%22Oral%20Abstract%20Session%22%7D,%7B%22key%22:%22Case-Based%20Panel%22%7D,%7B%22key%22:%22Clinical%20Science%20Symposium%22%7D,%7B%22key%22:%22Poster%20Discussion%20Session%22%7D,%7B%22key%22:%22Poster%20Session%22%7D,%7B%22key%22:%22Ticketed%20Session%22%7D%5D%7D


责任编辑:肿瘤资讯-饶运双
排版编辑:肿瘤资讯-饶运双


                   

版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。
2023ASCO带有二维码的大会图片.jpg   

评论
2023年05月13日
高阳阳
河北医科大学第四医院 | 放疗科
妇科肿瘤领域重磅研究
2023年05月13日
雷昕奕
永州市中心医院 | 胃肠外科
肿瘤治疗又有最新进展。
2023年05月13日
陈华福
厦门大学附属东南医院(解放军第175医院) | 外科
ASCO】一文速览2023 ASCO年